|
WRN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.00980026959985E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.77569999709948E-08 |
| Normal-vs-Stage2 |
6.67879999971532E-07 |
| Normal-vs-Stage3 |
2.09189999766934E-08 |
| Normal-vs-Stage4 |
1.23109999972115E-07 |
| Stage1-vs-Stage2 |
2.720400E-01 |
| Stage1-vs-Stage3 |
2.580200E-01 |
| Stage1-vs-Stage4 |
2.058600E-01 |
| Stage2-vs-Stage3 |
8.118800E-01 |
| Stage2-vs-Stage4 |
9.187000E-01 |
| Stage3-vs-Stage4 |
7.146400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.31630001237926E-09 |
| Normal-vs-AfricanAmerican |
4.039900E-03 |
| Normal-vs-Asian |
1.595560E-04 |
| Caucasian-vs-AfricanAmerican |
3.568600E-01 |
| Caucasian-vs-Asian |
5.817600E-01 |
| AfricanAmerican-vs-Asian |
6.743400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.50850007432746E-10 |
| Normal-vs-Female |
9.08380004549514E-09 |
| Male-vs-Female |
1.960170E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.10040000000922E-06 |
| Normal-vs-Age(41-60Yrs) |
6.6025995781871E-10 |
| Normal-vs-Age(61-80Yrs) |
1.38489999468305E-08 |
| Normal-vs-Age(81-100Yrs) |
4.738900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.215900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.325010E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.864800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.400800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.179800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.930800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.363000E-01 |
| Classical-VS-Follicular |
7.433700E-04 |
| Classical-VS-Other |
1.375450E-01 |
| Classical-VS-Normal |
4.42539999978564E-07 |
| Tall-VS-Follicular |
5.024600E-01 |
| Tall-VS-Other |
4.316200E-01 |
| Tall-VS-Normal |
4.14209999999304E-06 |
| Follicular-VS-Other |
7.121400E-01 |
| Follicular-VS-Normal |
2.00950034390246E-10 |
| Other-VS-Normal |
1.582570E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.98019950331729E-10 |
| Normal-vs-N1 |
1.85937999999108E-05 |
| N0-vs-N1 |
5.296200E-01 |
|
|
